Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program

Authors

  • Clara C Chan Department of Ophthalmology & Vision Sciences, University of Toronto, Toronto, ON, Canada.
  • C. Lisa Prokopich Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada.

DOI:

https://doi.org/10.18433/jpps29895

Abstract

Dry eye disease (DED) is a common inflammatory disorder of the ocular surface. Millions of people are affected by DED worldwide. Lifitegrast is a novel drug designed to inhibit DED-associated ocular inflammation. Four clinical trials have shown that lifitegrast is well tolerated and effective in improving symptoms and signs of DED over 12 weeks. A fifth trial showed long-term safety over 1 year. Lifitegrast has been in clinical use for more than one year in the United States and was recently approved in Canada (in December 2017). In this review, we discuss lifitegrast’s novel mechanism of action and provide an overview of its clinical trial program.

Downloads

Download data is not yet available.

Downloads

Published

2019-01-13

How to Cite

Chan, C. C., & Prokopich, C. L. (2019). Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye Disease: Overview of Clinical Trial Program. Journal of Pharmacy & Pharmaceutical Sciences, 22(1), 49–56. https://doi.org/10.18433/jpps29895

Issue

Vol. 22 (2019): Pages 1 - 130

Section

Review Articles

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.